JP5763758B2 - Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド - Google Patents

Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド Download PDF

Info

Publication number
JP5763758B2
JP5763758B2 JP2013517611A JP2013517611A JP5763758B2 JP 5763758 B2 JP5763758 B2 JP 5763758B2 JP 2013517611 A JP2013517611 A JP 2013517611A JP 2013517611 A JP2013517611 A JP 2013517611A JP 5763758 B2 JP5763758 B2 JP 5763758B2
Authority
JP
Japan
Prior art keywords
formula
compounds
compound
disorder
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013517611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531006A5 (OSRAM
JP2013531006A (ja
Inventor
マリー クラフィー ミッシェル
マリー クラフィー ミッシェル
エリザベス ダヴォレン ジェニファー
エリザベス ダヴォレン ジェニファー
アダムズ ロウ ジョン Iii
ジョセフ マザー ロバート
ジョセフ マザー ロバート
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2013531006A publication Critical patent/JP2013531006A/ja
Publication of JP2013531006A5 publication Critical patent/JP2013531006A5/ja
Application granted granted Critical
Publication of JP5763758B2 publication Critical patent/JP5763758B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013517611A 2010-07-08 2011-06-20 Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド Expired - Fee Related JP5763758B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36250510P 2010-07-08 2010-07-08
US61/362,505 2010-07-08
PCT/IB2011/052686 WO2012004698A1 (en) 2010-07-08 2011-06-20 Piperidinyl pyrimidine amides as kv7 potassium channel openers

Publications (3)

Publication Number Publication Date
JP2013531006A JP2013531006A (ja) 2013-08-01
JP2013531006A5 JP2013531006A5 (OSRAM) 2014-06-05
JP5763758B2 true JP5763758B2 (ja) 2015-08-12

Family

ID=44487037

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013517611A Expired - Fee Related JP5763758B2 (ja) 2010-07-08 2011-06-20 Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド

Country Status (11)

Country Link
US (1) US8883812B2 (OSRAM)
EP (1) EP2590961A1 (OSRAM)
JP (1) JP5763758B2 (OSRAM)
KR (1) KR101449348B1 (OSRAM)
CN (1) CN102971307A (OSRAM)
AU (1) AU2011275393B2 (OSRAM)
CA (1) CA2804165C (OSRAM)
MX (1) MX2013000138A (OSRAM)
SG (1) SG186409A1 (OSRAM)
WO (1) WO2012004698A1 (OSRAM)
ZA (1) ZA201300499B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
ES2885424T3 (es) 2013-03-15 2021-12-13 Knopp Biosciences Llc Imidazo(4,5-B)piridin-2-il amidas como activadores del canal Kv7
ES2960991T3 (es) 2014-09-12 2024-03-07 Biohaven Therapeutics Ltd Benzoimidazol-1,2-ilamidas como activadores del canal Kv7
JP7121144B2 (ja) * 2018-02-20 2022-08-17 ハー・ルンドベック・アクチエゼルスカベット Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体
IL310136A (en) 2018-03-19 2024-03-01 Knopp Biosciences Llc KV7 channel activator preparations and methods of use
AR119521A1 (es) * 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
AU2020350614A1 (en) * 2019-09-17 2022-03-31 Biohaven Therapeutics Ltd. Methods of use for Kv7 channel activators
WO2021119018A1 (en) * 2019-12-09 2021-06-17 The Board Of Trustees Of The Leland Stanford Junior University A method to improve sleep quality in the elderly by controlling excitability of hypocretin neurons
WO2021211867A1 (en) * 2020-04-16 2021-10-21 Attune Neurosciences, Inc. Kv7 modulators for treating sleep or anxiety disorders
WO2022047311A1 (en) * 2020-08-28 2022-03-03 Pfizer Inc. Computerized decision support tool and medical device for respiratory condition monitoring and care
GB202306914D0 (en) * 2023-05-10 2023-06-21 Sania Rx Ltd Method
CN119661413B (zh) * 2024-12-28 2025-06-24 齐鲁医药学院 Kv7钾离子通道开放剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361879A1 (en) * 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
US20080261918A1 (en) * 2004-12-17 2008-10-23 Graham Andrew Showell Silicon Compounds and Their Use
US7322249B2 (en) 2005-07-07 2008-01-29 Delphi Technologies, Inc. Mounting for a probe sensor
AU2006322461A1 (en) * 2005-09-09 2007-06-14 H. Lundbeck A/S Pyrimidine derivatives and their use as KCNQ potassium channels openers
US7683058B2 (en) * 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
US20090118285A1 (en) 2006-02-07 2009-05-07 H. Lundbeck A/S Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
BRPI0716715B1 (pt) * 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
EP2185149A1 (en) 2007-08-01 2010-05-19 H. Lundbeck A/S Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Also Published As

Publication number Publication date
SG186409A1 (en) 2013-02-28
MX2013000138A (es) 2013-03-05
AU2011275393A1 (en) 2013-01-10
EP2590961A1 (en) 2013-05-15
JP2013531006A (ja) 2013-08-01
US8883812B2 (en) 2014-11-11
KR20130031323A (ko) 2013-03-28
CA2804165A1 (en) 2012-01-12
AU2011275393B2 (en) 2014-04-10
US20130150391A1 (en) 2013-06-13
CA2804165C (en) 2015-02-24
WO2012004698A1 (en) 2012-01-12
KR101449348B1 (ko) 2014-10-08
ZA201300499B (en) 2013-09-25
CN102971307A (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
JP2013531006A (ja) Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド
RU2756512C1 (ru) Пролекарства кетамина, его композиции и применения
JP6805220B2 (ja) 治療上活性な化合物およびそれらの使用方法
US10590079B2 (en) Cyano-substituted indoles as LSD1 inhibitors
CN105814067B (zh) 作为钠通道调节剂的吡啶酮酰胺的前药
CN105026373B (zh) 作为钠通道调节剂的吡啶酮酰胺
CN110740993A (zh) 用作钠通道调节剂的氘代吡啶酮酰胺及其前药
EP3150592B1 (en) Alk kinase inhibitor, and preparation method and use thereof
WO2024067744A1 (zh) 杂环取代喹唑啉及其制备方法和应用
EP4253373A1 (en) Heteroaryl carboxamide compound
EP2875016B1 (en) Carbamate/urea derivatives
EP3807261B1 (en) Pyridinyl pyrazoles as modulators of roryt
JP3927228B2 (ja) Ｎｍｄａ／ｎｒ２ｂ拮抗物質としての３−フルオロ−ピペリジン
JP2021528405A (ja) ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール
WO2025051180A1 (zh) 内酰胺类衍生物及其应用
CN111727191A (zh) 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途
EP4587429B1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
US10538523B2 (en) 4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain
JP2013540752A (ja) カリウムチャネル関連疾患の治療のためのピリミドン
HK1177199A (en) Piperidinyl pyrimidine amides as kv7 potassium channel openers
EA041031B1 (ru) Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150611

R150 Certificate of patent or registration of utility model

Ref document number: 5763758

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees